Patel, S., Palazzolo, M. G., Antman, E. M., Braunwald, E., Carnicelli, A. P., Connolly, S. J., … Giugliano, R. P. (2023). Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin. In EUROPEAN HEART JOURNAL (Vol. 44).

Patel, S., M. G. Palazzolo, E. M. Antman, E. Braunwald, A. P. Carnicelli, S. J. Connolly, C. B. Granger, et al. “Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin.” In EUROPEAN HEART JOURNAL, Vol. 44, 2023.

Patel S, Palazzolo MG, Antman EM, Braunwald E, Carnicelli AP, Connolly SJ, et al. Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin. In: EUROPEAN HEART JOURNAL. 2023.

Patel, S., et al. “Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin.” EUROPEAN HEART JOURNAL, vol. 44, 2023.

Patel S, Palazzolo MG, Antman EM, Braunwald E, Carnicelli AP, Connolly SJ, Granger CB, Patel MR, Wallentin L, Ruff CT, Giugliano RP. Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin. EUROPEAN HEART JOURNAL. 2023.